Login / Signup

Peroxisome Proliferator-Activated Receptor Gamma Agonist Attenuates Liver Fibrosis by Several Fibrogenic Pathways in an Animal Model of Cholestatic Fibrosis.

Fatima Safira AlatasToshiharu MatsuuraAntonius Hocky PudjiadiStephanie WijayaTomoaki Taguchi
Published in: Pediatric gastroenterology, hepatology & nutrition (2020)
The PPAR-γ agonist inhibits HSC activation in vivo and attenuates liver fibrosis through several fibrogenic pathways. Potent fibrogenic factors such as PDGF, CTGF, and TGF-β1 were downregulated by the PPAR-γ agonist. Targeting PPAR-γ activity may be a potential strategy to control liver fibrosis.
Keyphrases
  • liver fibrosis
  • insulin resistance
  • fatty acid
  • skeletal muscle
  • smooth muscle
  • adipose tissue
  • risk assessment
  • anti inflammatory
  • binding protein
  • angiotensin ii